Cyclerion Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $3.6001
- Today's High:
- $4.1
- Open Price:
- $4.1
- 52W Low:
- $3.636
- 52W High:
- $25
- Prev. Close:
- $3.975
- Volume:
- 23898
Company Statistics
- Market Cap.:
- $10.40 million
- Book Value:
- 1.804
- Revenue TTM:
- $914000
- Operating Margin TTM:
- -4204.6%
- Gross Profit TTM:
- $-29749000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -82.85%
- Return on Equity TTM:
- -185.82%
Company Profile
Cyclerion Therapeutics Inc had its IPO on 2019-04-02 under the ticker symbol CYCN.
The company operates in the Healthcare sector and Biotechnology industry. Cyclerion Therapeutics Inc has a staff strength of 16 employees.
Stock update
Shares of Cyclerion Therapeutics Inc opened at $4.1 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $3.6 - $4.1, and closed at $3.83.
This is a -3.65% slip from the previous day's closing price.
A total volume of 23,898 shares were traded at the close of the day’s session.
In the last one week, shares of Cyclerion Therapeutics Inc have increased by +7.28%.
Cyclerion Therapeutics Inc's Key Ratios
Cyclerion Therapeutics Inc has a market cap of $10.40 million, indicating a price to book ratio of 1.7109 and a price to sales ratio of 17.4285.
In the last 12-months Cyclerion Therapeutics Inc’s revenue was $914000 with a gross profit of $-29749000 and an EBITDA of $-38396752. The EBITDA ratio measures Cyclerion Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Cyclerion Therapeutics Inc’s operating margin was -4204.6% while its return on assets stood at -82.85% with a return of equity of -185.82%.
In Q1, Cyclerion Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 14.1%.
Cyclerion Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-17.44 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cyclerion Therapeutics Inc’s profitability.
Cyclerion Therapeutics Inc stock is trading at a EV to sales ratio of 0.517 and a EV to EBITDA ratio of 0.529. Its price to sales ratio in the trailing 12-months stood at 17.4285.
Cyclerion Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $11.46 million
- Total Liabilities
- $7.53 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Cyclerion Therapeutics Inc ended 2024 with $11.46 million in total assets and $0 in total liabilities. Its intangible assets were valued at $11.46 million while shareholder equity stood at $3.93 million.
Cyclerion Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $7.53 million in other current liabilities, in common stock, $-266108000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $7.17 million and cash and short-term investments were $7.17 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Cyclerion Therapeutics Inc’s total current assets stands at $8.34 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $96000.00 compared to accounts payable of $3.93 million and inventory worth $0.
In 2024, Cyclerion Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Cyclerion Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $3.83
- 52-Week High
- $25
- 52-Week Low
- $3.636
- Analyst Target Price
- $4
Cyclerion Therapeutics Inc stock is currently trading at $3.83 per share. It touched a 52-week high of $25 and a 52-week low of $25. Analysts tracking the stock have a 12-month average target price of $4.
Its 50-day moving average was $3.59 and 200-day moving average was $8.23 The short ratio stood at 1.55 indicating a short percent outstanding of 0%.
Around 490.1% of the company’s stock are held by insiders while 4945.4% are held by institutions.
Frequently Asked Questions About Cyclerion Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is Zagociguat (CY6463), a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer’s disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018, a CNS-targeted sGC stimulator that is in preclinical trial for the treatment of neuropsychiatric diseases and disorders. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.